The role of mTOR inhibitors for treatment of sarcomas

Current Oncology Reports

Volumn 9, Issue 4, 2007, Pages 316-322

  Mita, Monica M ^a   Tolcher, Anthony W ^b  

^a CTRC Institute for Drug Development   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AP 23573; CAPECITABINE; CYCLOPHOSPHAMIDE; EVEROLIMUS; GEFITINIB; HYDROXYUREA; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; RAPAMYCIN; TEMSIROLIMUS;

ADVANCED CANCER; ANEMIA; ANGIOSARCOMA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER STAGING; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; GASTRITIS; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LEUKOPENIA; LIPOSARCOMA; LIVER FUNCTION TEST; LUNG NON SMALL CELL CANCER; MALIGNANT FIBROUS HISTIOCYTOMA; METASTASIS POTENTIAL; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHUMAN; OSTEOSARCOMA; PROSTATE CARCINOMA; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN TOXICITY; SOFT TISSUE SARCOMA; STOMATITIS; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SARCOMA; SIROLIMUS; SOFT TISSUE NEOPLASMS;

EID: 34447293996     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-007-0039-7     Document Type: Review

References (50)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Vezina C, Kudelski A, Sehgal SN: Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975, 28:721-726.
3. Baker A, Sidorowicz A, Sehgal SN, Vezina C: Rapamycin (AY-22,989), a new anti-fungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot (Tokyo) 1978, 31:539-545.
4. Eng CP, Sehgal SN, Vezina C: Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) 1984, 37:1231-1237.
5. Wiederrecht GJ, Sabers CJ, Brunn GJ, et al.: Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. Prog Cell Cycle Res 1995, 1:53-71.
6. Fruman DA, Wood MA, Gjertson CK, et al.: FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. Eur J Immunol 1995, 25:563-571.
7. Sekulic AH, Homme CC, Yin P, et al.: A direct link between the phosphoinositide-3-kinase-Akt signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000, 60:3504-3514.
8. Steck PA, Pershouse MA, Jasser SA, et al.: Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997, 15:356-362.
9. Neshat MS, Mellinghoff IK, Tran C, et al.: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001, 98:10314-10319.
10. Jefferies HB, Fumagalli S, Dennis PB, et al.: Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J 1997, 16:3693-3704.
11. Gingras AC, Raught B, Sonenberg N: eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulation of translation. Annu Rev Biochem 1999, 68:913-963.
12. Wullschleger S, Loewith R, Hall M: TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
13. Faive S, Kroemer G, Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev 2006, 5:671-688.
14. Kurmasheva RT, Huang S, Houghton PJ: Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer 2006, 95:955-960.
15. Ricci R, Maggiano N, Castri F, et al.: Role of PTEN in gastrointestinal stromal tumor progression. Arch Pathol Lab Med 2004, 128:421-425.
16. Saito T, Oda Y, Kawaguchi K, et al.: PTEN/MMAC1 gene mutation is a rare event in soft tissue sarcomas without specific balance translocation. Int J Cancer 2003, 104:175-178.
17. Wan X, Helman LJ: Levels of PTEn protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cells. Oncogene 2003, 22:8205-8211.
18. Gibbons JJ, Discafani C, Peterson R, et al.: The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse in vivo [abstract]. Proc Am Assoc Cancer Res 1999, 40:301.
19. Hidalgo M, Buckner JC, Erlichman C, et al.: A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006, 12:5755-5763.
20. Raymond E, Alexandre J, Faivre S, et al.: Safety and pharmacokynetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004, 22:2336-2347.
21. Atkins MB, Hidalgo M, Stadler MW, et al.: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced renal cell carcinoma. J Clin Oncol 2004, 22:909-918.
22. Hudes G, Carducci M, Tomczack P, et al.: A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR+IFN in the treatment of first line, poor-risk patients with advanced renal cell carcinoma [abstract]. J Clin Oncol Proc ASCO 2006, 24:LBA4.
23. Chan S, Scheulen ME, Johnston S, et al.: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced breast cancer. J Clin Oncol, 2005, 23:5314-5322.
24. Carpenter JT, Roche H, Campone M, et al.: Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer [abstract]. J Clin Oncol Proc ASCO 2005, 23:564.
25. Galanis E, Buckner JC, Maurer MJ, et al.: Phase II trial of temskolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005, 23:5294-5304.
26. Fourouzesh B, Buckner J, Adjei A, et al.: Phase I, bioavailability and pharmacokinetic study of oral dosage of CCI-779 administered to patients with advanced solid malignancies. Proceedings of the 13th EORTC-NCI-AACR symposium [abstract]. Eur J Cancer 2002, 38(Suppl 7):168.
27. O'Reilly T, Vaxelaire J, Muller M, et al.: In vivo activity of RAD001, an orally active rapamycin derivative, in experimental tumor models [abstract]. Proc Am Assoc Cancer Res 2002, 43:71.
28. Lane H, Schnell C, Theuer A, et al.: Antiangiogenic activity of RAD001, an orally active anticancer agent [abstract]. Proc Am Assoc Cancer Res 2002, 43:184.
29. O'Donnell A, Faivre S, Judson I, et al.: A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumors [abstract]. J Clin Oncol Proc ASCO 2003, 22:803.
30. Amato RJ, Misellati A, Khan M, Chiang S: A phase II trial of RAD001 in patients with metastatic renal cell carcinoma [abstract]. J Clin Oncol Proc ASCO 2006, 24:4530.
31. Lerut E, Roskams T, Goossens E, et al.: Molecular pharmacodynamic (MPD) evaluation of dose and schedule of RAD 001 (everolimus) in patients with operable prostate carcinoma [abstract]. J Clin Oncol Proc ASCO 2005, 23:3071.
32. Reardon D, Quinn JA, Rich JN, et al.: A phase I trial of imatinib, hydroxyurea and RAD 001 for patients with recurrent malignant glioma [abstract]. J Clin Oncol Proc ASCO 2006, 24:1580.
33. Yao JC, Phan AT, Chang DZ, et al.: Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET) [abstract]. J Clin Oncol Proc ASCO 2006, 24:4042.
34. Milton DT, Kris MG, Azzoli CG, et al.: Phase I/II trial of gefitinib and RAD001 (everolimus) in patients with advanced non-small cell lung cancer [abstract]. J Clin Oncol Proc ASCO 2005, 23:7104.
35. Clackson T, Metcalf CA, Rivera VM, et al.: Broad anti-tumor activity of AP23573, an mTOR inhibitor in clinical development [abstract]. J Clin Oncol Proc ASCO 2003, 21:882.
36. Mita M, Rowinsky EK, Goldston ML, et al.: Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of AP23573, an mTOR inhibitor administered IV daily X5 every other week in patients with refractory or advanced malignancies [abstract]. J Clin Oncol Proc ASCO 2004, 22:3076.
37. Desai AA, Janish L, Berk LR, et al.: A phase I trial of a novel mTOR inhibitor AP23573 administered weekly in patients with refractory or advanced malignancies: A pharmacokinetic (PK) and pharmacodynamic (PD) analysis [abstract]. J Clin Oncol Proc ASCO 2004, 22:3150.
38. Perotti A, Maur M, Vigano L, et al.: Phase Ib pharmacokinetic (PK) and pharmacodynamic (PD) study to define the optimal dose for combining the mTOR inhibitor AP23573 with capecitabine [abstract]. J Clin Oncol Proc ASCO 2006, 24:3065.
39. Feldman E, Giles F, Roboz G, et al.: A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies [abstract]. J Clin Oncol Proc ASCO 2005, 23:6631.
40. Chawla SP, Tolcher AW, Staddon AP, et al.: Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcomas [abstract]. J Clin Oncol Proc ASCO 24:9505.
41. Blay JY, Van Glabbeke M, Verweij J, et al.: Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 2003, 39:64-69.
42. Le Cesne A, Blay JY, Judson I, et al.: Phase 2 study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial. J Clin Oncol 2005, 23:576-584.
43. Le Cesne A, Judson I, Crowther D, et al.: Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000, 18:2676-2684.
44. Van Glabbeke M, Verweij J, Judson I, et al.: Progression-free rate as the principal end-point for phase II trials in soft tissue sarcomas. Eur J Cancer 2002, 38:543-549.
45. Sankhala K, Chawala SP, Seegers M, et al.: Early response evaluation of therapy with AP23573 (an mTOR inhibitor) in sarcoma fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) scan [abstract]. J Clin Oncol Proc ASCO 2005, 23:9028.
46. Okuno SH, Mahoney MR, Bailey HH, et al.: A multicenter phase 2 consortium study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcoma [abstract]. J Clin Oncol Proc ASCO 2006, 24:9504.
47. Schuetze SM, Baker LH, Maki RG: Sirolimus reduced tumor-related morbidity and resulted in biochemical and radiographic response in patients with progressive sarcoma [abstract]. J Clin Oncol Proc ASCO 2006, 24:9503.
48. Heinrich MC, Corless CL, Blanke CD, et al.: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006, 24:4764-4774.
49. van Oosterom A, Reichardt P, Blay J, et al.: A phase I/II trial of the oral mTOR-inhibitor Everolimus (E) and Imatinib Mesylate (IM) in patients with gastrointestinal stromal tumor (GIST) refractory to IM: Study update [abstract]. J Clin Oncol Proc ASCO 2005, 23:9033.
50. Duran D, Siu LL, Oza AM, et al.: Characterization of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006, 42:1875-1880.